Conquering Cancer event

Glycanostics developed early-stage, highly-accurate and unique cancer diagnostic test based on analysis of glycans from blood serum. Our PCT patents cover 11 types of solid tumours.

INCITE is a biotech pre-start up initiative within cancer therapy.

INCITE is creating a platform for improving T cell therapy through 3D printing and cell technology

InProTher is a biotech from Copenhagen (BioInnovation Institute – Novo Nordisk Foundation).

We are developing effective cancer vaccines targeting tumor-specific Human EndoRetroviruses (HERVs) using Adeno and RNA vectors. This is a paradigm shift in immunotherapy.

French biotechnology company, pioneering the development of next-generation cancer vaccines based on induced pluripotent stem cells (iPSCs) technology, as a new paradigm in cancer treatment.

Cellis is a European biotech company, with a focus in cell-based oncology therapy. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC) for the treatment of solid tumors. MDC is based on the ground-breaking discovery of the biologic TRAIN mechanism, which enables efficient and highly targeted delivery of a wide range of active moieties and compounds directly into the cytoplasm of cancer cells. As a result, cancer cells are killed, macrophages phagocyte them, present tumor-specific antigens and activate immune system. MDC changes the tumor microenvironment creating immune resistance to cancer re-growth. Preparation is underway to progress our technology to the first in human clinical trials in Q3 2024.